News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Lonza Group Full Year Results 2008
February 4, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Record EBIT of CHF 441 million (+8%; +12% on a comparable basis) Net income growth of 39% further strengthening the investment-grade balance sheet and supporting the ability to generate further sustainable growth
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
Lonza
MORE ON THIS TOPIC
Layoff Tracker
Schrödinger Downsizes by 7% in Savings Push
May 21, 2025
·
209 min read
·
BioSpace Editorial Staff
Podcast
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
May 21, 2025
·
2 min read
·
Heather McKenzie
Opinion
Evolving Market Pressures Force Biopharma Companies to Cut Assets Early
May 21, 2025
·
5 min read
·
Michael N. Abrams
Collaboration
CRISPR Expands Focus, Pays Up To $95M in Sirius’ siRNA Pact
May 20, 2025
·
2 min read
·
Tristan Manalac
